{"id":101882,"date":"2025-03-28T16:35:13","date_gmt":"2025-03-28T16:35:13","guid":{"rendered":"https:\/\/www.mymsd.ch\/it\/?p=101882"},"modified":"2025-12-02T11:13:52","modified_gmt":"2025-12-02T11:13:52","slug":"melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia","status":"publish","type":"post","link":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/","title":{"rendered":"Melanoma: il rischio di recidiva pu\u00f2 essere ridotto con l\u2019immunoterapia"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" height=\"487\" width=\"1024\" src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Banner-Melanoma-SGDV.jpg?w=1024\" alt=\"Persone in scene di vita quotidiana, banner KEYTRUDA per stadi di melanoma IIB\u2013IV\" class=\"wp-image-101888\" srcset=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Banner-Melanoma-SGDV.jpg 1156w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Banner-Melanoma-SGDV.jpg?resize=300,143 300w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Banner-Melanoma-SGDV.jpg?resize=768,365 768w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Banner-Melanoma-SGDV.jpg?resize=1024,487 1024w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Banner-Melanoma-SGDV.jpg?resize=320,152 320w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Banner-Melanoma-SGDV.jpg?resize=120,57 120w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--496148f350b36cc16c774ee5020aa5fb mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--f840acf8f15a803af70e5e88a8baac19 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color has-teal-500-color has-text-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--b889108ed6f0c7d9411507f69717aa8c\">Molti\/e pazienti con melanoma in stadio IIB e IIC non possono essere guariti\/e solo con la resezione.<sup>2<\/sup><strong> <\/strong><\/h4>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--51c3f2f02c55218a749857223d59a552\">Le recidive si verificano frequentemente nel melanoma in stadio IIB e IIC<sup>3<\/sup><br><sup><br><\/sup><\/h5>\n\n\n<figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--c05f541b35f21d5f2544c7e1dc5f37dd\">\n                    <img loading=\"lazy\" decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--full wp-image-101889\"\n        src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Melanoma-SGDV-Recidive.jpg?quality=80&#038;lossy=1\"\n        width=\"1024\"\n        height=\"487\"\n                alt=\"Chart showing recurrence and metastasis rates in melanoma stages IIB and IIC, including affected organs\"\n            \/>\n            <\/figure>\n\n\n\n<div style=\"height:80px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<section class=\"mhh-mcn-v1-section mhh-mcn-v1-section--fe4e2df9ecba7fdb3071f9ee808c408c mhh-mcn-section mhh-mcn-v1-section--align-full\">\n    <div class=\"mhh-mcn-container\">\n    \n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--da33f02e8bf16440110cd08566ffaaee\"><mark class=\"has-inline-color has-teal-700-color\">Per pazienti con melanoma in stadio IIB\/IIC \u00e8 disponibile un&#8217;opzione terapeutica di MSD.<sup>1,*<\/sup><\/mark><\/h4>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--422d114a8d6ff3658824f8be33c463b6\"><mark class=\"has-inline-color has-black-color\">Terapia adiuvante con KEYTRUDA\u00ae per i suoi\/le sue pazienti con melanoma<sup>1<\/sup><\/mark><\/h5>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ce6525e7ad9325a5bc6c0dcf69304b7e\"><mark class=\"has-inline-color has-black-color\">KEYTRUDA<sup>\u00ae<\/sup> iin monoterapia \u00e8 indicato nel trattamento adiuvante di pazienti adulti con melanoma allo stadio IIB o IIC completamente rimosso.<sup>1,* <\/sup>Nello studio KEYNOTE-716, la terapia precoce con KEYTRUDA\u00ae ha potuto ridurre il rischio di recidiva e migliorare la sopravvivenza libera da recidive.<sup>4<\/sup><\/mark><\/p>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--554bcf7188a1b85a4812f149d2040f55\"><mark class=\"has-inline-color has-black-color\">Nello studio di omologazione KEYNOTE-716, il rischio di recidiva \u00e8 stato ridotto del 38% nei pazienti con melanoma in stadio IIB\/IIC trattati con KEYTRUDA\u00ae rispetto al placebo (dati a 4 anni, follow-up mediano di 52.8 mesi).\u2074 Il profilo di sicurezza era coerente con quello gi\u00e0 noto, senza nuovi segnali di rischio.\u2074<\/mark><\/p>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--83fe55e0caf4ea2e12f24af64a183675\"><mark class=\"has-inline-color has-black-color\">Vantaggio clinicamente significativo rispetto al placebo<sup>4<\/sup><\/mark><\/h5>\n\n\n<figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--f1cf7c34fc4ca4950c474fe5a9e0fab7\">\n                    <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--full wp-image-101890\"\n        src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Melanoma-SGDV-RFS-DMFS.jpg?quality=80&#038;lossy=1\"\n        width=\"1024\"\n        height=\"390\"\n        loading=\"lazy\"        alt=\"Graph showing 38% risk reduction of recurrence and 41% risk reduction of distant metastases in melanoma\"\n            \/>\n            <\/figure>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading  has-border-color has-has-red-border-color-border-color mhh-mcn-v1-heading--center mhh-mcn-v1-heading mhh-mcn-v1-heading--ad6a18f9f5c0e79be6b96e0834b8b517\"><strong><mark class=\"has-inline-color has-teal-700-color\">Indirizzi i suoi\/le sue pazienti con melanoma stadio IIB\/IIC ad un\/a oncologo\/a!<\/mark><\/strong><\/h5>\n\n    <\/div>\n<\/section>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--b0ab8ab982d11c57a653d287d448d85d\">KEYTRUDA\u00ae \u2013&nbsp; dal 2015 una opzione terapeutica per pazienti con melanoma<sup>5<\/sup><\/h4>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--4e52c15c74746af20ca2cd11749259e5\">Alla MSD, lavoriamo costantemente per fornire terapie che offrano ai\/alle pazienti oncologici\/che una maggiore qualit\u00e0 della vita e pi\u00f9 tempo. KEYTRUDA\u00ae \u00e8 omologato per il trattamento del melanoma negli adulti negli stadi ad alto rischio IIB\/IIC* e III e nello stadio IV.<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<section class=\"mhh-mcn-v1-section mhh-mcn-v1-section--1cdb7b016c514d41245f298167d97780 mhh-mcn-section mhh-mcn-v1-section--align-full\">\n    <div class=\"mhh-mcn-container\">\n    \n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--8b6578759ffaa7350aa01e573311fd3d\"><mark class=\"has-inline-color has-white-color\"><strong>Il Prof. Dr. Reinhard Dummer sui progressi della terapia immunologica<\/strong><\/mark><\/h4>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--62e74312ff89a900e684a37e6d0ed0ae\">Guardi il video<\/p>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--b6323245e3880732dd5a81e9f8ab1ebe mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--25d3fc3de4a1ea63a78ebdc62b92972a mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-6\">\n    \n\n<div  class=\"inpsyde-brightcove__player\" style=\"position: relative\">\n\n    \n    <video-js class=\"video-js vjs-16-9\" data-embed=\"default\" data-player=\"wpDhMYhEmz\" data-account=\"4090876667001\" data-video-id=\"6364902980112\" aria-label=\"Video\" controls poster-url=\"https:\/\/cf-images.us-east-1.prod.boltdns.net\/v1\/static\/4090876667001\/ba6d2928-1fc6-4de2-9fff-8c5173ad8ed5\/9efc5f9f-860b-4156-a953-34c264e65b9f\/1280x720\/match\/image.jpg\"><\/video-js>\n\n        <img\n        class=\"inpsyde-brightcove__poster\"\n        src=\"https:\/\/cf-images.us-east-1.prod.boltdns.net\/v1\/static\/4090876667001\/ba6d2928-1fc6-4de2-9fff-8c5173ad8ed5\/9efc5f9f-860b-4156-a953-34c264e65b9f\/1280x720\/match\/image.jpg\"\n        alt=\"\"\n        fetchpriority=\"high\"\n        decoding=\"async\"\n        aria-hidden=\"true\"\n    \/>\n    \n    \n    <script src=\"https:\/\/players.brightcove.net\/4090876667001\/wpDhMYhEmz_default\/index.min.js\"><\/script>\n<\/div>\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--1a59582cea3c9b801e39b3d2a3655f67 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-6\">\n    \n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--4736b7699f9414be282ea581e7bd9b04\"><mark class=\"has-inline-color has-white-color\"><em>\u00abQuando faccio la prima conversazione con un paziente con melanoma metastatico, gli dico: <\/em><br><br><em>Il nostro obiettivo \u00e8 curarla.\u00bb<\/em><\/mark><\/p>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n    <\/div>\n<\/section>\n\n\n\n<div style=\"height:44px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--bc7da2b4ac394199145248a956e69fa3 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--71b46671f596a39daae2bbb37080009c mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--fde106220b94f94d0c971e192ac64cfd mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--746bcdf951174aa908ae3b5eadb42d7b mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-8 mhh-mcn-column--l-8\">\n    \n\n<h4 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--3db6ea709fdbb71fccd163303cf9b134\">Ulteriori informazioni <br>sulle opzioni terapeutiche con KEYTRUDA\u00ae <br>per il melanoma<\/h4>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--bb8e29cf5a62ea66500f931a92efcedd\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--5ac2f4273638d52bce3cc8e6803c9823 mhh-mcn-v1-link--is-variation mhh-mcn-v1-link--button-primary\" href=\"https:\/\/www.mymsd.ch\/it\/products\/keytruda\/indicazioni\/melanom\/\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Keytruda Indicazioni Melanom\">\n                    <span class=\"mhh-mcn-v1-link__label\">Alle opzioni terapeutiche<\/span>\n                <\/a><\/div>\n\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--7372b3f3c60dc21c368e718352d62788 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-4 mhh-mcn-column--l-4\">\n    \n<figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--2ecdd8b3fc19f1e09950aeb3233649d0\">\n                    <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--medium wp-image-94539\"\n        src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/08\/Melanom-2.png?w=300&#038;quality=80&#038;lossy=1\"\n        width=\"300\"\n        height=\"300\"\n        loading=\"lazy\"        alt=\"Illustration of skin cross-section with hair follicles\"\n            \/>\n            <\/figure>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:24px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\r\n<div class=\"inpsyde-iframe is-responsive has-transparent-background-color\">\r\n    <iframe loading=\"lazy\" height=\"400\" referrerpolicy=\"no-referrer-when-downgrade\" title=\"Questo contenuto \u00e8 stato rilevante per Lei?\" src=\"https:\/\/go.screver.com\/msd-ch-cx\/newsroom-articles?lang=it&amp;hideHeader=true\" width=\"100%\"><\/iframe>\r\n<\/div>\n\n\n<section class=\"mhh-mcn-v1-section mhh-mcn-v1-section--98095c7329093fe592fffee4e7bc87eb mhh-mcn-section mhh-mcn-v1-section--align-full\">\n    <div class=\"mhh-mcn-container\">\n    \n\n<h3 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color has-text-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--e94657ebad452fee692fbe855d3bd372\" style=\"color:#000000\">Related Content<\/h3>\n\n\n<div class=\"mhh-mcn-v1-content-items mhh-mcn-v1-content-items--7f1129b17fe2b9a9d5f305754bebc6ac wp-block-mconnect-theme-curated-content mhh-mcn-layout--columns mhh-mcn-columns mhh-mcn-v1-columns--c749fc431e07efe173069178a87d9ed0 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\" dir=\"ltr\" lang=\"en-US\">\n    <div class=\"mhh-mcn-columns-inner\">\n        <div\n    class=\"mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-4 mhh-mcn-v1-content-item mhh-mcn-v1-content-item--33e6b4551c1092d3512bac5ab0a5f0cd mhh-mcn-v1-content-item--type-post mhh-mcn-v1-content-item--card-style mhh-mcn-v1-content-item--display-media-style mhh-mcn-v1-content-item--has-featured-image\" dir=\"ltr\" lang=\"en-US\">\n    <div class=\"mhh-mcn-v1-content-item-featured-image\">\n    <figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--c9936dfb40314ad5fcb3318c818cfe4d with-aspect-ratio with-aspect-ratio--content-grid\">\n    <div class=\"figure-outer\">\n    <div class=\"figure-inner\">\n                            <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--2048x2048 wp-image-96864\"\n        src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2024\/02\/MSD2931-KEYTRUDA-Melanom-KN716-Bilder-fuer-mymsd-600x400-IT-V02-150.png?w=1250&#038;quality=80&#038;lossy=1\"\n        width=\"1250\"\n        height=\"833\"\n        loading=\"lazy\"        alt=\"Nuova opzione di trattamento con KEYTRUDA\u00ae per il melanoma \u00a0\"\n            \/>\n                <\/div>\n    <\/div>\n    <\/figure>\n<\/div>\n\n<article class=\"mhh-mcn-v1-content-item-content\">\n    <section class=\"mhh-mcn-v1-content-item-content-body\">\n        \n<span class=\"mhh-mcn-v1-content-item-primary-tag mhh-mcn-v1-content-item-primary-tag--c06ec76831703497d2b89abb588910eb\" title=\"L&#039;elemento \u00e8 stato taggato come: Melanoma\">\n    Melanoma<\/span>\n        <header class=\"mhh-mcn-v1-content-item-header\">\n    \n    <span class=\"mhh-mcn-v1-content-item-icon-type mhh-mcn-v1-content-item-icon-type--post\">\n    <span class=\"mhh-mcn-v1-content-item-icon-type__icon\">\n    \n<svg width=\"1em\" height=\"1em\" class=\"mh-icon mh-icon--kind-generic mh-icon--name-arrow-right mh-icon--arrow-right\" role=\"img\" aria-hidden=\"true\">\n    \n    \n    <use xlink:href=\"https:\/\/www.mymsd.ch\/it\/wp-content\/themes\/cex-wpvip-mhh-mconnect-theme-new-3.0\/modules\/icons\/resources\/icons\/svg\/generic\/arrow-right.svg#arrow-right\"><\/use>\n<\/svg>\n    <\/span>\n    <\/span>\n    <h2 class=\"mhh-mcn-v1-content-item-title mhh-mcn-v1-content-item-title--c06ec76831703497d2b89abb588910eb\">\n    \n    <a class=\"mhh-mcn-v1-content-item-title__link\" href=\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news\/nuova-opzione-di-trattamento-con-keytruda-per-il-melanoma\/\" target=\"_blank\" rel=\"noopener noreferrer\">\n        Nuova opzione di trattamento con KEYTRUDA\u00ae per il melanoma \u00a0    <\/a>\n    <\/h2>\n\n    <\/header>\n\n        <p class=\"mhh-mcn-v1-content-item-excerpt mhh-mcn-v1-content-item-excerpt--c06ec76831703497d2b89abb588910eb\">\n    Swissmedic ha approvato KEYTRUDA\u00ae per il trattamento del melanoma ad alto rischio nello stadio IIB\/IIC.<\/p>\n        \n<div class=\"mhh-mcn-v1-content-item-meta mhh-mcn-badge-container\">\n    \n    \n    <\/div>\n    <\/section>\n    <div class=\"mhh-mcn-v1-content-item-footer\">\n    \n    <div class=\"mhh-mcn-v1-content-item-call-to-action mhh-mcn-v1-content-item-call-to-action--c06ec76831703497d2b89abb588910eb\">\n    Per saperne di pi\u00f9<\/div>\n\n    <\/div>\n<\/article>\n<\/div>\n<div\n    class=\"mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-4 mhh-mcn-v1-content-item mhh-mcn-v1-content-item--fdab389d75ea18ebc729cb063191f643 mhh-mcn-v1-content-item--type-post mhh-mcn-v1-content-item--card-style mhh-mcn-v1-content-item--display-media-style mhh-mcn-v1-content-item--has-featured-image\" dir=\"ltr\" lang=\"en-US\">\n    <div class=\"mhh-mcn-v1-content-item-featured-image\">\n    <figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--db2ff7273707b834b2af0b209083f6f0 with-aspect-ratio with-aspect-ratio--content-grid\">\n    <div class=\"figure-outer\">\n    <div class=\"figure-inner\">\n                            <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--2048x2048 wp-image-95629\"\n        src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/10\/MSD2916-Header-IT-635x475px-V01.jpg?w=635&#038;quality=80&#038;lossy=1\"\n        width=\"635\"\n        height=\"475\"\n        loading=\"lazy\"        alt=\"Entrambe le opzioni di dosaggio di KEYTRUDA\u00ae per il melanoma da adesso sono rimborsate dalle casse malati\"\n            \/>\n                <\/div>\n    <\/div>\n    <\/figure>\n<\/div>\n\n<article class=\"mhh-mcn-v1-content-item-content\">\n    <section class=\"mhh-mcn-v1-content-item-content-body\">\n        \n<span class=\"mhh-mcn-v1-content-item-primary-tag mhh-mcn-v1-content-item-primary-tag--c06ec76831703497d2b89abb588910eb\" title=\"L&#039;elemento \u00e8 stato taggato come: Melanoma\">\n    Melanoma<\/span>\n        <header class=\"mhh-mcn-v1-content-item-header\">\n    \n    <span class=\"mhh-mcn-v1-content-item-icon-type mhh-mcn-v1-content-item-icon-type--post\">\n    <span class=\"mhh-mcn-v1-content-item-icon-type__icon\">\n    \n<svg width=\"1em\" height=\"1em\" class=\"mh-icon mh-icon--kind-generic mh-icon--name-arrow-right mh-icon--arrow-right\" role=\"img\" aria-hidden=\"true\">\n    \n    \n    <use xlink:href=\"https:\/\/www.mymsd.ch\/it\/wp-content\/themes\/cex-wpvip-mhh-mconnect-theme-new-3.0\/modules\/icons\/resources\/icons\/svg\/generic\/arrow-right.svg#arrow-right\"><\/use>\n<\/svg>\n    <\/span>\n    <\/span>\n    <h2 class=\"mhh-mcn-v1-content-item-title mhh-mcn-v1-content-item-title--c06ec76831703497d2b89abb588910eb\">\n    \n    <a class=\"mhh-mcn-v1-content-item-title__link\" href=\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news\/entrambe-le-opzioni-di-dosaggio-di-keytruda-per-il-melanoma-da-adesso-sono-rimborsate-dalle-casse-malati\/\" target=\"_blank\" rel=\"noopener noreferrer\">\n        Entrambe le opzioni di dosaggio di KEYTRUDA\u00ae per il melanoma da adesso sono rimborsate dalle casse malati    <\/a>\n    <\/h2>\n\n    <\/header>\n\n        <p class=\"mhh-mcn-v1-content-item-excerpt mhh-mcn-v1-content-item-excerpt--c06ec76831703497d2b89abb588910eb\">\n    Novit\u00e0: entrambe le opzioni di dosaggio di KEYTRUDA\u00ae (Pembrolizumab) per il melanoma sono state inserite nell&#8217;elenco delle specialit\u00e0 dell&#8217;Ufficio federale della sanit\u00e0 pubblica (UFSP)<\/p>\n        \n<div class=\"mhh-mcn-v1-content-item-meta mhh-mcn-badge-container\">\n    \n    \n    <\/div>\n    <\/section>\n    <div class=\"mhh-mcn-v1-content-item-footer\">\n    \n    <div class=\"mhh-mcn-v1-content-item-call-to-action mhh-mcn-v1-content-item-call-to-action--c06ec76831703497d2b89abb588910eb\">\n    Per saperne di pi\u00f9<\/div>\n\n    <\/div>\n<\/article>\n<\/div>\n<div\n    class=\"mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-4 mhh-mcn-v1-content-item mhh-mcn-v1-content-item--b30e8060a6e1e6b4bee35dba9fe75d1a mhh-mcn-v1-content-item--type-post mhh-mcn-v1-content-item--card-style mhh-mcn-v1-content-item--display-media-style mhh-mcn-v1-content-item--has-featured-image\" dir=\"ltr\" lang=\"en-US\">\n    <div class=\"mhh-mcn-v1-content-item-featured-image\">\n    <figure class=\"mhh-mcn-v1-image mhh-mcn-v1-image--8cc9641158ae94838c37caedb7663716 with-aspect-ratio with-aspect-ratio--content-grid\">\n    <div class=\"figure-outer\">\n    <div class=\"figure-inner\">\n                            <img decoding=\"async\"\n        class=\"mhh-mcn-image mhh-mcn-image--2048x2048 wp-image-93852\"\n        src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/06\/NOVITA-sottopagina-dedicata-arti-1.png?w=1380&#038;quality=80&#038;lossy=1\"\n        width=\"1380\"\n        height=\"1380\"\n        loading=\"lazy\"        alt=\"NOVIT\u00c0: sottopagina dedicata al melanoma per il nostro portale per pazienti \u00abmsd-gesundheit.ch\u00bb\"\n            \/>\n                <\/div>\n    <\/div>\n    <\/figure>\n<\/div>\n\n<article class=\"mhh-mcn-v1-content-item-content\">\n    <section class=\"mhh-mcn-v1-content-item-content-body\">\n        \n<span class=\"mhh-mcn-v1-content-item-primary-tag mhh-mcn-v1-content-item-primary-tag--c06ec76831703497d2b89abb588910eb\" title=\"L&#039;elemento \u00e8 stato taggato come: Melanoma\">\n    Melanoma<\/span>\n        <header class=\"mhh-mcn-v1-content-item-header\">\n    \n    <span class=\"mhh-mcn-v1-content-item-icon-type mhh-mcn-v1-content-item-icon-type--post\">\n    <span class=\"mhh-mcn-v1-content-item-icon-type__icon\">\n    \n<svg width=\"1em\" height=\"1em\" class=\"mh-icon mh-icon--kind-generic mh-icon--name-arrow-right mh-icon--arrow-right\" role=\"img\" aria-hidden=\"true\">\n    \n    \n    <use xlink:href=\"https:\/\/www.mymsd.ch\/it\/wp-content\/themes\/cex-wpvip-mhh-mconnect-theme-new-3.0\/modules\/icons\/resources\/icons\/svg\/generic\/arrow-right.svg#arrow-right\"><\/use>\n<\/svg>\n    <\/span>\n    <\/span>\n    <h2 class=\"mhh-mcn-v1-content-item-title mhh-mcn-v1-content-item-title--c06ec76831703497d2b89abb588910eb\">\n    \n    <a class=\"mhh-mcn-v1-content-item-title__link\" href=\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news\/novita-sottopagina-dedicata-al-melanoma-per-il-nostro-portale-per-pazienti-msd-gesundheit-ch\/\" target=\"_blank\" rel=\"noopener noreferrer\">\n        NOVIT\u00c0: sottopagina dedicata al melanoma per il nostro portale per pazienti \u00abmsd-gesundheit.ch\u00bb    <\/a>\n    <\/h2>\n\n    <\/header>\n\n        <p class=\"mhh-mcn-v1-content-item-excerpt mhh-mcn-v1-content-item-excerpt--c06ec76831703497d2b89abb588910eb\">\n    Trasmettere conoscenze testate dal punto di vista medico spiegate semplicemente? Il nostro portale per i pazienti &#8220;msd-gesundheit.ch&#8221; mira a fare proprio questo.<\/p>\n        \n<div class=\"mhh-mcn-v1-content-item-meta mhh-mcn-badge-container\">\n    \n    \n    <\/div>\n    <\/section>\n    <div class=\"mhh-mcn-v1-content-item-footer\">\n    \n    <div class=\"mhh-mcn-v1-content-item-call-to-action mhh-mcn-v1-content-item-call-to-action--c06ec76831703497d2b89abb588910eb\">\n    Per saperne di pi\u00f9<\/div>\n\n    <\/div>\n<\/article>\n<\/div>\n    <\/div>\n\n    <\/div>\n\n    <\/div>\n<\/section>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--4a91073cfc5134869172824e6108f655\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--67a7fe7ddd4f88e8ea0fe998e28c77df\" href=\"mailto:%20dpoc.switzerland@msd.com\" target=\"_self\" aria-label=\"All&#039;occorrenza, \u00e8 possibile richiedere copie delle pubblicazioni degli studi all&#039;indirizzo dpoc.switzerland@msd.com.\">\n                    <span class=\"mhh-mcn-v1-link__label\">All&#8217;occorrenza, \u00e8 possibile richiedere copie delle pubblicazioni degli studi all&#8217;indirizzo dpoc.switzerland@msd.com.<\/span>\n                <\/a><\/div>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--573d5d18de2d25729ab3c1bfd44ae665\"><strong><em>Abbreviazioni<\/em><\/strong><em>:<\/em><\/h5>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--13b8b65d8d78286adf66dedbc73ac30d\"><strong><em>DMFS: <\/em><\/strong><em>sopravvivenza libera da metastasi a distanza  (distant metastasis-free survival); <strong>HR:<\/strong> Hazard Ratio; <strong>IC<\/strong>: intervallo di confidenza; <strong>Q3W:<\/strong> ogni tre settimane; <strong>Q6W:<\/strong> ogni seisettimane; <strong>RFS:<\/strong> sopravvivenza libera da recidive (recurrence-free survival).<\/em><\/p>\n\n\n\n<h5 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--05487796c01aaa6a16400a730f1af66c\"><strong><em>Riferimenti bibliografici:<\/em><\/strong><\/h5>\n\n\n\n<ol class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--0beef22bde78b8b9fdb4a3c16919479d mhh-mcn-list mhh-mcn-v2-clist--ordered mhh-mcn-v2-clist--ordered-decimal\" dir=\"ltr\" lang=\"en-US\" start=\"1\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <em>Informazione professionale di KEYTRUDA\u00ae (pembrolizumab), <a href=\"https:\/\/swissmedicinfo.ch\/showText.aspx?textType=FI&amp;lang=IT&amp;authNr=66231&amp;supportMultipleResults=1\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">www.swissmedicinfo.ch<\/a>, ultima consultazione il 21.3.2025.<br>* A causa dell&#8217;incompletezza dei dati clinici in sede di valutazione della domanda, queste indicazioni vengono omologate in via temporanea (art. 9a legge sugli agenti terapeutici). L&#8217;omologazione temporanea \u00e8 vincolata necessariamente all&#8217;adempimento tempestivo delle condizioni. Una volta soddisfatte le condizioni, l&#8217;omologazione temporanea pu\u00f2 essere trasformata in un&#8217;omologazione ordinaria.<sup>1<\/sup><\/em><br>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <em>Gershenwald JE, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer (AJCC) Eighth Edition Cancer Staging Manual. CA Cancer J Clin. 2017;67(6):472 \u2013 492.<\/em><br>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <em>Lee AY, Droppelmann N, Panageas KS, et al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol. 2017;24(4):939-946. doi: 10.1245\/s10434-016-5642-0.<\/em><br><em><strong>Disegno dello studio<\/strong>: studio retrospettivo su 738 pazienti adulti\/e da un database mantenuto in modo prospettico di una istituzione con melanoma cutaneo primario resecato in stadio patologico II (AJCC, 7\u00aa edizione). Tutti i\/le pazienti sono stati trattati\/e presso il Memorial Sloan Kettering Cancer Center tra gennaio 1993 e dicembre 2013. Nei\/nelle pazienti \u00e8 stato fatta una stadiazione patologica dei linfonodi mediante biopsia del linfonodo sentinella o dissezione elettiva dei linfonodi. Il periodo mediano di osservazione per i\/le pazienti con melanoma in stadio IIB e IIC \u00e8 stato rispettivamente di 50.2 e 46.2 mesi.<br><\/em>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <em>Luke JJ, et al. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024 Mar 7:JCO2302355. doi: 10.1200\/JCO.23.02355. Online ahead of print.\u00a0<\/em><br><em><strong>Disegno dello studio:<\/strong> studio di fase III multicentrico, in doppio cieco, randomizzato, controllato con placebo (parte 1 in cieco, parte 2 rechallenge\/crossover in aperto): 976 pazienti (\u2265 12 anni) con melanoma in stadio IIB o IIC completamente resecato (popolazione ITT), randomizzazione (1:1): KEYTRUDA\u00ae 200 mg o 2 mg\/kg di peso corporeo fino a un massimo di 200 mg (pazienti padiatrici \u2265 12 anni) ogni 3 settimane (n = 487)* rispetto al placebo (n = 489). Trattamento dei pazienti inizialmente fino a 1 anno o fino alla comparsa di recidiva o tossicit\u00e0 inaccettabile (Parte 1), in caso di recidiva trattamento rechallenge (Parte 2) fino a 2 anni fino alla comparsa di una recidiva o tossicit\u00e0 inaccettabile. Pazienti che a parte l\u2019operazione avevano ricevuto in precedenza un altro trattamento del melanoma sono stati esclusi dallo studio. Endpoint primario: sopravvivenza libera da recidiva (RFS) nella popolazione complessiva. La RFS \u00e8 stata valutata dallo sperimentatore ed \u00e8 stata definita come il tempo trascorso tra la data di randomizzazione e la data della comparsa della prima recidiva (locale, regionale o metastasi a distanza) o del decesso, a seconda di quale evento si sia verificato per primo. *Per informazioni dettagliate sul dosaggio, consultare l\u2019informazione professionale.<\/em><br>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <em><a href=\"https:\/\/compendium.ch\/product\/1346803-keytruda-inf-konz-100-mg-4ml\">https:\/\/compendium.ch\/product\/1346803-keytruda-inf-konz-100-mg-4ml<\/a>, ultima consultazione il 21.3.2025.<\/em>    <\/li>\n\n<\/ol>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a646c26a5a883fb4a3276f3301802706\"><em><em><em><em><em>Prima della prescrizione, consulti l\u2019informazione professionale completa pubblicata su<\/em><\/em><\/em><\/em><\/em> <em><em><em><em><em><em><a href=\"https:\/\/swissmedicinfo.ch\/showText.aspx?textType=FI&amp;lang=DE&amp;authNr=66231&amp;supportMultipleResults=1\" target=\"_blank\" rel=\"noreferrer noopener\">www.swissmedicinfo.ch<\/a><\/em><\/em><\/em><\/em>.<\/em><\/em><\/p>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--41192979da5aa9543f304bdd4d0838bc\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--b3e851e53f2a9d7059720dfdfb1cc524 mhh-mcn-v1-link--is-variation mhh-mcn-v1-link--button-primary\" href=\"https:\/\/www.swissmedicinfo-pro.ch\/showText.aspx?textType=FI&#038;lang=IT&#038;authNr=66231&#038;supportMultipleResults=1\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Informazione professionale di KEYTRUDA\u00ae\">\n                    <span class=\"mhh-mcn-v1-link__label\">Informazione professionale di KEYTRUDA\u00ae<\/span>\n                <\/a><\/div>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--c969102f79fc88aaaa0edb746cc6fe50\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--e38e412d4e8385aa8db8313a3b0ab85a mhh-mcn-v1-link--is-variation mhh-mcn-v1-link--button-primary\" href=\"https:\/\/www.mymsd.ch\/it\/succinctstatement\/keytruda\/\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Informazione professionale breve di KEYTRUDA\u00ae\">\n                    <span class=\"mhh-mcn-v1-link__label\">Informazione professionale breve di KEYTRUDA\u00ae<\/span>\n                <\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Molti\/e pazienti con melanoma in stadio IIB e IIC non possono essere guariti\/e solo con la resezione.<\/p>\n","protected":false},"author":1413,"featured_media":101919,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"hide_header":false,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"icon":null,"job_code":"","hide_featured_image":true,"primary_tag":419,"editor_notices":[],"mconnectHideShareThis":false,"footnotes":"","sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[236,311],"tags":[226,419],"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[501],"ga4_page_businessunit":[507],"ga4_page_campaign":[],"ga4_page_content_purpose":[],"ga4_page_customer_journey_stage":[],"ga4_page_customer_specialty":[],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[713],"ga4_page_product":[],"ga4_page_region":[],"ga4_page_therapeuticarea":[],"tx-therapeutic-area":[280,229],"tx-product":[270],"tx-pathology":[233],"tx-content-type":[227],"tx-active-ingredient":[],"access":[],"user_status":[],"user_role":[],"class_list":["post-101882","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-onco-news-it","category-oncology","tag-keytruda","tag-melanoma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Melanoma: il rischio di recidiva pu\u00f2 essere ridotto con l&#039;immunoterapia - MyMSD.ch IT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Melanoma: il rischio di recidiva pu\u00f2 essere ridotto con l&#039;immunoterapia - MyMSD.ch IT\" \/>\n<meta property=\"og:description\" content=\"Molti\/e pazienti con melanoma in stadio IIB e IIC non possono essere guariti\/e solo con la resezione.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/\" \/>\n<meta property=\"og:site_name\" content=\"MyMSD.ch IT\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-28T16:35:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-02T11:13:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Teaser-Melanoma-SGDV_2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"sthost\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"sthost\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/\"},\"author\":{\"name\":\"sthost\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/#\/schema\/person\/6bc7965d9f4713a7dc95aeb8da3a1e43\"},\"headline\":\"Melanoma: il rischio di recidiva pu\u00f2 essere ridotto con l\u2019immunoterapia\",\"datePublished\":\"2025-03-28T16:35:13+00:00\",\"dateModified\":\"2025-12-02T11:13:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/\"},\"wordCount\":324,\"publisher\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Teaser-Melanoma-SGDV_2.jpg\",\"keywords\":[\"Keytruda\",\"Melanoma\"],\"articleSection\":[\"Onco News IT\",\"Oncology\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/\",\"url\":\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/\",\"name\":\"Melanoma: il rischio di recidiva pu\u00f2 essere ridotto con l'immunoterapia - MyMSD.ch IT\",\"isPartOf\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Teaser-Melanoma-SGDV_2.jpg\",\"datePublished\":\"2025-03-28T16:35:13+00:00\",\"dateModified\":\"2025-12-02T11:13:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/#primaryimage\",\"url\":\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Teaser-Melanoma-SGDV_2.jpg\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Teaser-Melanoma-SGDV_2.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"Melanoma: il rischio di recidiva pu\u00f2 essere ridotto con l'immunoterapia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.mymsd.ch\/it\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Melanoma: il rischio di recidiva pu\u00f2 essere ridotto con l\u2019immunoterapia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/#website\",\"url\":\"https:\/\/www.mymsd.ch\/it\/\",\"name\":\"MyMSD.ch IT\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.mymsd.ch\/it\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/#organization\",\"name\":\"MSD Switzerland\",\"url\":\"https:\/\/www.mymsd.ch\/it\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/10\/cropped-myMSD-logo.png\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/10\/cropped-myMSD-logo.png\",\"width\":4084,\"height\":692,\"caption\":\"MSD Switzerland\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/#\/schema\/person\/6bc7965d9f4713a7dc95aeb8da3a1e43\",\"name\":\"sthost\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9e48f2711556efbfa56650f54374dccc9a99738b8c5579cfd48f2501a53bdd55?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9e48f2711556efbfa56650f54374dccc9a99738b8c5579cfd48f2501a53bdd55?s=96&d=mm&r=g\",\"caption\":\"sthost\"},\"url\":\"https:\/\/www.mymsd.ch\/it\/author\/sthost\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Melanoma: il rischio di recidiva pu\u00f2 essere ridotto con l'immunoterapia - MyMSD.ch IT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/","og_locale":"it_IT","og_type":"article","og_title":"Melanoma: il rischio di recidiva pu\u00f2 essere ridotto con l'immunoterapia - MyMSD.ch IT","og_description":"Molti\/e pazienti con melanoma in stadio IIB e IIC non possono essere guariti\/e solo con la resezione.","og_url":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/","og_site_name":"MyMSD.ch IT","article_published_time":"2025-03-28T16:35:13+00:00","article_modified_time":"2025-12-02T11:13:52+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Teaser-Melanoma-SGDV_2.jpg","type":"image\/jpeg"}],"author":"sthost","twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"sthost","Tempo di lettura stimato":"3 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/#article","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/"},"author":{"name":"sthost","@id":"https:\/\/www.mymsd.ch\/it\/#\/schema\/person\/6bc7965d9f4713a7dc95aeb8da3a1e43"},"headline":"Melanoma: il rischio di recidiva pu\u00f2 essere ridotto con l\u2019immunoterapia","datePublished":"2025-03-28T16:35:13+00:00","dateModified":"2025-12-02T11:13:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/"},"wordCount":324,"publisher":{"@id":"https:\/\/www.mymsd.ch\/it\/#organization"},"image":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Teaser-Melanoma-SGDV_2.jpg","keywords":["Keytruda","Melanoma"],"articleSection":["Onco News IT","Oncology"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/","url":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/","name":"Melanoma: il rischio di recidiva pu\u00f2 essere ridotto con l'immunoterapia - MyMSD.ch IT","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/#primaryimage"},"image":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Teaser-Melanoma-SGDV_2.jpg","datePublished":"2025-03-28T16:35:13+00:00","dateModified":"2025-12-02T11:13:52+00:00","breadcrumb":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/#primaryimage","url":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Teaser-Melanoma-SGDV_2.jpg","contentUrl":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Teaser-Melanoma-SGDV_2.jpg","width":1536,"height":1024,"caption":"Melanoma: il rischio di recidiva pu\u00f2 essere ridotto con l'immunoterapia"},{"@type":"BreadcrumbList","@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mymsd.ch\/it\/"},{"@type":"ListItem","position":2,"name":"Melanoma: il rischio di recidiva pu\u00f2 essere ridotto con l\u2019immunoterapia"}]},{"@type":"WebSite","@id":"https:\/\/www.mymsd.ch\/it\/#website","url":"https:\/\/www.mymsd.ch\/it\/","name":"MyMSD.ch IT","description":"","publisher":{"@id":"https:\/\/www.mymsd.ch\/it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mymsd.ch\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.mymsd.ch\/it\/#organization","name":"MSD Switzerland","url":"https:\/\/www.mymsd.ch\/it\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.mymsd.ch\/it\/#\/schema\/logo\/image\/","url":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/10\/cropped-myMSD-logo.png","contentUrl":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/10\/cropped-myMSD-logo.png","width":4084,"height":692,"caption":"MSD Switzerland"},"image":{"@id":"https:\/\/www.mymsd.ch\/it\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.mymsd.ch\/it\/#\/schema\/person\/6bc7965d9f4713a7dc95aeb8da3a1e43","name":"sthost","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.mymsd.ch\/it\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9e48f2711556efbfa56650f54374dccc9a99738b8c5579cfd48f2501a53bdd55?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9e48f2711556efbfa56650f54374dccc9a99738b8c5579cfd48f2501a53bdd55?s=96&d=mm&r=g","caption":"sthost"},"url":"https:\/\/www.mymsd.ch\/it\/author\/sthost\/"}]}},"_links":{"self":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/posts\/101882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/users\/1413"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/comments?post=101882"}],"version-history":[{"count":24,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/posts\/101882\/revisions"}],"predecessor-version":[{"id":104686,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/posts\/101882\/revisions\/104686"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/media\/101919"}],"wp:attachment":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/media?parent=101882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/categories?post=101882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tags?post=101882"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_audience?post=101882"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_birn_id?post=101882"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_branding?post=101882"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_businessunit?post=101882"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_campaign?post=101882"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=101882"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=101882"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=101882"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_experience?post=101882"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_indication?post=101882"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_material_intent?post=101882"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_product?post=101882"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_region?post=101882"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=101882"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-therapeutic-area?post=101882"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-product?post=101882"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-pathology?post=101882"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-content-type?post=101882"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-active-ingredient?post=101882"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/access?post=101882"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/user_status?post=101882"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/user_role?post=101882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}